Business Wire

ICRYPEX

30.4.2021 11:02:08 CEST | Business Wire | Press release

Share
Turkey’s Most Advanced Crypto Trading Platform ICRYPEX Announces Joint Venture

Focusing their investments on technology and financial technology, Hedef Girişim Sermayesi Yatırım Ortaklığı A.Ş. and İdealist Danışmanlık A.Ş is now partnering with ICRYPEX Cryptocurrency Exchange , one of the Turkey’s leading crypto trading platforms. Hedef Girişim Sermayesi Yatırım Ortaklığı and İdealist Danışmanlık acquire 30% of ICRYPEX Cryptocurrency Exchange.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210430005021/en/

ICRYPEX Cryptocurrency Exchange provides services to its customers with its 129 full time employees. ICRYPEX offers its investors a cutting-edge, super-fast and low commission multi-asset crypto trading platform while supporting crypto currency wallet services. ICRYPEX also makes a difference in the sector with its 24/7 phone support.

ICRYPEX Cryptocurrency Exchange stands out amongst other crypto exchanges with its unique technological infrastructure and the high transaction speed it provides to its investors. Developing its own technologies, ICRYPEX provides its investors with less than 10 milliseconds processing time, matching engines and blockchain investments.

Taking firm steps towards being a global brand, ICRYPEX has become the name and jersey sponsor of the Men's Basketball First Team of the Beşiktaş JK, which is one of the biggest clubs of Turkey in January 2021. ICRYPEX has made a first in the world and made sponsorship payment in Bitcoin.

ICRYPEX has also become Turkey's first cryptocurrency exchange listing AVAX chains developed by a Turkish computer scientist with Avalanche protocol.

ICRYPEX is also the first and only cryptocurrency exchange listing USD and USDT currencies simultaneously. Since February 2019 the company has focused on second phase developments and has developed its current products such as website, matching engines, storage-sweeping services in-house.

Hedef Girişim Sermayesi Yatırım Ortaklığı makes investments predominantly in the financial technology area. Ftech Labs Bilişim A.Ş., Fintables Bilişim Teknolojileri A.Ş., Eko Hesap Bilgi Teknolojileri A.Ş., İdealist Danışmanlık A.Ş., İnfo Yatırım Menkul Değerler A.Ş are among the companies in which Hedef Girişim has a share.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lattice to Showcase Industrial FPGA Innovations at FPGAWorld Conference 202625.8.2026 22:00:00 CEST | Press release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced its exhibition plan for the upcoming FPGAWorld Conference 2026, taking place on Sept. 8, 2026, in Stockholm, Sweden. As part of the event, Lattice will deliver technical presentations and host a demo showcase focused on how its low power FPGA solutions are advancing Industrial IoT and sensor bridging applications. Who: Lattice Semiconductor What / When (GMT+2): Tuesday, Sept. 8, 2026 Lattice Demo Showcase Presentations (Track: 12:20 – 13:35, Room Brave 05) “Solving Your Power Puzzle: Lattice FPGAs’ Path to Uncompromised Low Power” “Practical Security Fundamentals for FPGA Engineers” Where: AFRY, Frösundaleden 2A, 169 70 Solna, Sweden The FPGAWorld Conference is an international forum for researchers, engineers, teachers, students, and hackers. It covers topics such as complex analog/digital/software FPGA SoC systems, FPGA/ASIC-based products, educational and industrial cases,

France Becomes First Official Participant at Expo 2030 Riyadh25.8.2026 19:40:00 CEST | Press release

France is the first country to officially sign its Participation Contract for Expo 2030 Riyadh, a major milestone in its preparations and growing international momentum. The signing took place on the sidelines of the visit to France by His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260825634516/en/ The ceremony in Paris was attended by H.H. Prince Faisal bin Farhan Al Saud, Minister of Foreign Affairs of the Kingdom of Saudi Arabia, and Dimitri S. Kerkentzes, Secretary General of the BIE. The Participation Contract was signed by Talal Al-Marri, Chief Executive Officer of Expo 2030 Riyadh, and Jacques Maire, Chairman of the Compagnie Française des Expositions (COFREX). The agreement formally establishes France’s participation in Expo 2030 Riyadh, providing the framework for its presence throughout the six-month event. It spec

Saudi Arabia and BIE Sign See Agreement for Expo 2030 Riyadh, Advancing Framework for International Participation25.8.2026 19:17:00 CEST | Press release

The Kingdom of Saudi Arabia and the Bureau International des Expositions (BIE) have signed the See Agreement for Expo 2030 Riyadh, formally establishing the legal and administrative framework that will support Official Participants throughout their journey to the World Expo. The signing took place on the sidelines of the visit to France by His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260825419959/en/ H.H. Prince Faisal bin Farhan Al Saud, Minister of Foreign Affairs of the Kingdom of Saudi Arabia, and Dimitri S. Kerkentzes, Secretary General of the BIE, at the ceremony. The ceremony was attended by H.H. Prince Faisal bin Farhan Al Saud, Minister of Foreign Affairs of the Kingdom of Saudi Arabia, Dimitri S. Kerkentzes, Secretary General of the BIE, and Talal Al-Marri, CEO of Expo 2030 Riyadh. The See Agreement sets out the

The LYCRA Company Reimagines the Trade Show Experience at Intertextile25.8.2026 18:11:00 CEST | Press release

Immersive Co-Creation District Showcases New Fiber Innovations and Value Chain Collaboration The LYCRA Company, a global leader in fiber and technology solutions for the apparel industry, is reimagining the trade show experience at Intertextile Shanghai Apparel Fabrics Autumn Edition, which opened today in China. Building on the success of last year's ALL IN concept, the company has expanded its co-creation vision into a 356-square-meter Lifestyle District featuring partners Jingzili New Material, JYT Textile, Lianxingfa Knitting, and Trend Textile. The district is part of a larger 895-square-meter pavilion showcasing a total of 19 co-exhibitors. Together, they demonstrate how innovations in fiber, fabric, and garments can be combined to create compelling solutions for both work and play. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260821281698/en/ The LYCRA Company expands its co-creation vision through an immersive Life

BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA25.8.2026 16:40:00 CEST | Press release

TEVIMBRA plus ZIIHERA and chemotherapy is the first and only immunotherapy-based regimen to deliver more than two years of median OS in first-line HER2+ GEA, regardless of PD-L1 statusRegimen poised to become standard of care in this difficult-to-treat disease. BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of adult patients with unresectable locally advanced or metastatic HER2-positive (HER2+) gastric, gastroesophageal junction, or esophageal adenocarcinoma (GEA). The approval is supported by results from the Phase 3 HERIZON-GEA-01 trial, which were published in The New England Journal of Medicine earlier this year. GEA, which includes adenocarcinomas of the stomach, gastroesophageal junction and e

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye